Clinical trials: Lymphoma, Non-Hodgkin
Leukemia, Lymphoma
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005606
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- Northwestern University
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back…
- Conditions
- Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03011814
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- City of Hope Medical Center
B-cell Lymphomas
High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse.
- Trial name
- SCNSL1 (NCT00801216)
- Testing
- High-dose sequential chemotherapy and autologous transplant
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Andrés José Maria Ferreri
Peripheral T-cell Lymphoma
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a Phase I/II, open-label, single-arm study investigating the combination of chidamide and golidocitinib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06757387
- Testing
- chidamide and golidocitinib
- Volunteers
- 45 people
- Sponsor
- Peking University Cancer Hospital & Institute
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage…
- Trial name
- Pola-R-ICE (NCT04833114)
- Testing
- Polatuzumab Vedotin, Mabthera, Ifosfamide
- Where
- 64 sites in Austria, Germany and 2 more
- Volunteers
- 306 people
- Sponsor
- GWT-TUD GmbH
Non Hodgkin's Lymphoma
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
- Trial name
- NCT01789723
- Testing
- Fusilev, Folotyn
- Sponsor
- Acrotech Biopharma Inc.
B-cell Non Hodgkin Lymphoma
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
- Trial name
- NCT06707259
- Testing
- anti-CD19 IL10/IL15 CAR-NK
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Obesity, Mild
EGPSS for Weight Management in an in Vivo Human Model
ndoscopic bariatric and metabolic therapies (EBMTs) have introduced more convenient, minimally invasive, and safe approaches to weight management.
- Trial name
- NCT07186959
- Testing
- endoscopic gastric purse-string suturing
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Liu Yan
Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
This clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with Philadelphia Chromosome (Ph) Negative B-ALL undergoing inpatient induction therapy.
- Conditions
- Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL
- Trial name
- NEOMA ALL (NCT06785324)
- Testing
- Nutrition Intervention, Exercise intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment.
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides
- Trial name
- NCT03278782
- Testing
- Pembrolizumab, Romidepsin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Periodontitis, Generalized, Moderate
Er:YAG Laser Treatment of Moderate Chronic Periodontitis
The Er:YAG laser possesses specific characteristics allowing to be used in non-surgical periodontal treatment. The aim of the resent study was to evaluate the long-term clinical effectiveness of Er:YAG laser monotherapy in the…
- Trial name
- NCT05217823
- Testing
- Er:YAG laser, hand instruments
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Plovdiv Medical University
B-cell Lymphoma
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
- Trial name
- CARMA-01 (NCT06002659)
- Testing
- CAR20(NAP)-T, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Lymphoma, Large Cell, Diffuse
Chemotherapy for Participants With Lymphoma
The primary purpose of this study is to help answer the following research questions: To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell…
- Trial name
- NCT00436280
- Testing
- enzastaurin, gemcitabine, rituximab
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Sezary Syndrome, Cutaneous T Lymphoma
Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies
Sezary syndrome (SS) is a rare, aggressive and advanced form of cutaneous T lymphoma with a poor prognosis (5-year survival rate varying between 24% and 52%). The treatments are only suspensive with short-term remissions.
- Trial name
- SURPASSe (NCT05206045)
- Testing
- Standard of care
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or…
- Trial name
- NCT02589145
- Testing
- Lenalidomide, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Tinnitus
Sub-chronic Neurostimulation Delivered in the Middle Ear for Tinnitus Suppression
The objectives of this study are to evaluate the safety and efficacy of applying electrical stimulation on the promontorium (EPS) for the suppression of tinnitus in a sub-chronic stimulation regimen.
- Trial name
- NCT01549145
- Testing
- Nimbus Multifunctional Stimulator
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- EstimME Ltd.
Lymphoma, T-Cell, Peripheral, Febrile Neutropenia
Cohort of Peripheral T Cell Lymphoma
Prospective, observational cohort study of peripheral T cell lymphoma. Purpose is to investigate the complication including febrile neutropenia in the era of pegylated G-CSF prophylaxis.
- Trial name
- NCT02364466
- Where
- 18 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Korea Cancer Center Hospital
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.